Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.53 | 0.08 | 0.05 | -0.02 |
| FCF Yield | -35.86% | -47.56% | -25.51% | -6.83% |
| EV / EBITDA | -1.82 | -1.93 | -2.81 | -3.21 |
| Quality | ||||
| ROIC | -276.00% | -563.79% | -144.10% | -56.77% |
| Gross Margin | 64.47% | 58.44% | 44.98% | 48.81% |
| Cash Conversion Ratio | 0.81 | 0.95 | 0.84 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.54% | -22.35% | -29.11% | 76.91% |
| Free Cash Flow Growth | -12.08% | 16.97% | -32.01% | -96.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.52 | 0.18 | 0.65 | 0.61 |
| Interest Coverage | -413.70 | -389.61 | -625.43 | -14.46 |
| Efficiency | ||||
| Inventory Turnover | 0.57 | 0.47 | 0.27 | 1.24 |
| Cash Conversion Cycle | -66.05 | -117.90 | 1,046.26 | -3.90 |